07Z0.F LEPU MED.T.B. SP.GDR O.N.
- Market cap
- -
- P/E
- 385.0x
- P/B
- 12.89x
- ROE
- 5.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 07Z0.F undervalued?
Graham numberThe Graham number of LEPU MED.T.B. SP.GDR O.N. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LEPU MED.T.B. SP.GDR O.N. fundamental analysis
No fundamental analysis for LEPU MED.T.B. SP.GDR O.N. yet.
LEPU MED.T.B. SP.GDR O.N. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LEPU MED.T.B. SP.GDR O.N.
Lepu Medical Technology (Beijing) Co., Ltd., together with its subsidiaries, engages in the research, development, and manufacturing of cardiac interventional medical devices in China and internationally. The company operates through three segments: Medical Devices; Pharmaceuticals; and Medical Services and Health Management. It offers medical devices, including cardiovascular devices, in vitro diagnostics, surgical instruments, peripheral blood vessels, blood purification, …
Full company profileLEPU MED.T.B. SP.GDR O.N. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
LEPU MED.T.B. SP.GDR O.N. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 10.7B | 10.6B | 7.98B | 6.10B | 6.48B | 6.17B |
| Gross Profit | 6.50B | 6.63B | 5.13B | 3.72B | 4.15B | 3.70B |
| Operating Income | 2.70B | 2.86B | 1.84B | 717M | 1.54B | 1.18B |
| EBITDA | - | 3.29B | 2.24B | 967M | 2.03B | 1.15B |
| Net Income | 1.72B | 2.20B | 1.26B | 247M | 962M | 904M |
| EPS | 0.95 | 1.17 | 0.67 | 0.13 | 0.52 | 0.49 |
| Balance Sheet | ||||||
| Total Assets | 20.7B | 24.5B | 25.0B | 24.6B | 26.1B | 26.2B |
| Total Liabilities | 8.43B | 8.11B | 7.52B | 7.83B | 8.38B | 8.40B |
| Shareholders' Equity | 11.5B | 15.1B | 16.0B | 15.2B | 16.1B | 16.4B |
| Cash & Short-term Investments | 3.80B | 5.47B | 4.22B | 3.72B | 4.43B | 3.86B |
| Cash Flow | ||||||
| Operating Cash Flow | 3.06B | 2.79B | 990M | 735M | 1.52B | - |
| Capital Expenditure | 984M | 905M | 845M | 659M | 643M | 920M |
| Free Cash Flow | 2.08B | 1.89B | 146M | 75.8M | 874M | 219M |
| Ratios | ||||||
| ROE | 15.0% | 14.5% | 7.9% | 1.6% | 6.0% | 5.5% |
| ROA | 8.3% | 9.0% | 5.0% | 1.0% | 3.7% | 3.5% |
| Net Profit Margin | 16.1% | 20.8% | 15.8% | 4.0% | 14.8% | 14.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
LEPU MED.T.B. SP.GDR O.N. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- 70.8%
- Ex-dividend date
- Jun 28, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 682M | 0.37 | 70.8% |
| 2024 | CNY 991M | 0.53 | 401.3% |
| 2023 | CNY 769M | 0.41 | 61.1% |
| 2022 | CNY 636M | 0.34 | 28.8% |
| 2021 | CNY 587M | 0.33 | 34.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Jun 23, 2016.
Who owns LEPU MED.T.B. SP.GDR O.N.
Ownership data of LEPU MED.T.B. SP.GDR O.N. is not available yet.
LEPU MED.T.B. SP.GDR O.N. company profile
- Company name
- LEPU MED.T.B. SP.GDR O.N.
- Ticker
- 07Z0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 8,689
- Fiscal year end
- December
- Address
- No. 37 Chaoqian Road, Beijing, China, 102200
- Phone
- 86 10 5830 5102
- Website
- lepumedical.com
About LEPU MED.T.B. SP.GDR O.N.
Lepu Medical Technology (Beijing) Co., Ltd., together with its subsidiaries, engages in the research, development, and manufacturing of cardiac interventional medical devices in China and internationally. The company operates through three segments: Medical Devices; Pharmaceuticals; and Medical Services and Health Management. It offers medical devices, including cardiovascular devices, in vitro diagnostics, surgical instruments, peripheral blood vessels, blood purification, ultrasound imaging, and orthopedic products; pharmaceutical products for cardiovascular, digestive, central nervous, and respiratory systems, as well as antimicrobial, nutrition, traditional Chinese medicine, lowering blood sugar, and health food; and medical services and health management, such as medical services, AI, home appliances, and medical aesthetics and daily chemical products. The company is also involved in investment activities; trading; technological development; and pension services. It exports its products. The company was founded in 1999 and is based in Beijing, China.
LEPU MED.T.B. SP.GDR O.N. management
7- Dr. Zhongjie PuChairman & CTO · born 1963
- Ms. Fei PuCEO & Non Independent Director · born 1989
- Ms. Yong Wang CPASenior VP & CFO · born 1973
- Ms. Weina JiangSecretary of the Board · born 1979
- Mr. Zhan Jiang WeiSenior Deputy General Manager · born 1972
- Mr. Bing Feng ZhangDeputy General Manager · born 1980
- Ms. Xiaoying FengDeputy General Manager · born 1974